성기 사마귀 : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Genital Warts Emerging Therapy and TPP Insights

Thelansis's "Genital Warts Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Genital Warts Overview

Genital warts, clinically termed condylomata acuminata, are highly contagious, benign anogenital neoplasms overwhelmingly driven by infection with low-risk human papillomavirus (HPV) genotypes, specifically types 6 and 11. Transmitted primarily through direct mucocutaneous contact during sexual activity, the virus intimately infects the basal keratinocytes; while the vast majority of immunocompetent individuals mount an effective cellular immune response and spontaneously clear the virus, persistent infection induces profound cellular proliferation. Clinically presenting as flesh-colored, exophytic, "cauliflower-like" papules or plaques, definitive histopathological diagnosis is hallmarked by the pathognomonic presence of koilocytes-squamous epithelial cells demonstrating hyperchromatic, enlarged nuclei surrounded by distinct perinuclear halos. Because the underlying viral reservoir frequently persists in adjacent normal tissue despite visible lesion clearance, clinical recurrence rates are notoriously high. Consequently, the therapeutic paradigm strictly focuses on macroscopic tumor destruction and symptomatic relief, utilizing a stratified approach of patient-applied immunomodulatory or antimitotic agents (such as imiquimod or podofilox) and provider-administered ablative interventions (including cryotherapy, trichloroacetic acid, or surgical excision). Most importantly, the global standard of care now heavily prioritizes primary prevention, leveraging the highly efficacious prophylactic 9-valent HPV vaccine to robustly neutralize these viral vectors and profoundly curtail disease incidence.

Key Highlights

• In Italy, prevalent cases of genital warts are projected to increase from 945,224 to 1,013,513, indicating a growing disease burden despite vaccination efforts.
• High recurrence rates remain a defining challenge due to persistent viral reservoirs and non-curative treatment approaches.
• The disease carries a significant psychosocial and quality-of-life burden, beyond its clinical manifestation.
• Increasing uptake of HPV vaccination programs is expected to gradually reduce incidence, particularly in younger populations.
• Limited innovation in curative therapies highlights a continued unmet need for durable and virus-targeting treatments.

Market Overview

• The France genital warts market is projected to grow from $390M to $570M, reflecting strong market expansion.
• Market growth is driven by:
• High recurrence leading to repeat treatment cycles
• Continued use of procedure-based and topical therapies
• Despite preventive vaccination, market value remains supported by existing prevalent patient pool and treatment demand.
• Increasing awareness and screening contribute to higher diagnosis and treatment rates.
• Future market dynamics will depend on vaccination coverage expansion and development of more durable therapeutic options.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Shanghai Bovax Biotechnology Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)